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Background: Themembrane protein Rft1 was proposed to flip Man5GlcNAc2-PP-dolichol (M5-DLO) to the ER lumen for
N-glycoprotein biosynthesis.
Results: Rft1-null Trypanosoma brucei has a normal steady-state level of mature dolichol-linked oligosaccharide (mDLO) and
significant N-glycosylation.
Conclusion:Rft1 is not required forM5-DLO flipping in vivo but aids conversion ofM5-DLO tomDLOby anothermechanism.
Significance: The M5-DLO flippase remains to be identified.
Mature dolichol-linked oligosaccharides (mDLOs) needed
for eukaryotic proteinN-glycosylation are synthesized by amul-
tistep pathway in which the biosynthetic lipid intermediate
Man5GlcNAc2-PP-dolichol (M5-DLO) flips from the cytoplas-
mic to the luminal face of the endoplasmic reticulum. The en-
doplasmic reticulum membrane protein Rft1 is intimately
involved in mDLO biosynthesis. Yeast genetic analyses impli-
cated Rft1 as the M5-DLO flippase, but because biochemical
tests challenged this assignment, the function of Rft1 remains
obscure. To understand the role of Rft1, we sought to analyze
mDLO biosynthesis in vivo in the complete absence of the pro-
tein. Rft1 is essential for yeast viability, and no Rft1-null organ-
isms are currently available. Here, we exploited Trypanosoma
brucei (Tb), an early diverging eukaryotewhoseRft1 homologue
functions in yeast. We report that TbRft1-null procyclic
trypanosomes grow nearly normally. They have normal steady-
state levels ofmDLO and significantN-glycosylation, indicating
robust M5-DLO flippase activity. Remarkably, the mutant cells
have 30–100-fold greater steady-state levels of M5-DLO than
wild-type cells. All N-glycans in the TbRft1-null cells originate
frommDLO indicating that theM5-DLO excess is not available
for glycosylation. These results suggest that rather than facili-
tatingM5-DLO flipping, Rft1 facilitates conversion ofM5-DLO
to mDLO by another mechanism, possibly by acting as an
M5-DLO chaperone.
Protein N-glycosylation is ubiquitous in eukaryotes. N-
Linked oligosaccharides direct folding, quality control, and
degradation of most proteins that enter the secretory pathway
and also influence their subsequent trafficking (1). The impor-
tance of N-linked oligosaccharides is evinced by the discovery
of human congenital disorders of glycosylation (2), in which
errors in oligosaccharide synthesis or assembly result in devel-
opmental, neurological, and metabolic dysfunction, often with
life-threatening consequences. Consequently, detailed knowl-
edge of the mechanisms of N-linked oligosaccharide assembly
is critically important for understanding human physiology.
The N-linked oligosaccharide moiety is assembled on a
dolichyl diphosphate lipid carrier before being transferred en
bloc to glycosylation sequons (Asn-Xaa-(Ser/Thr)) in nas-
cent proteins as they enter the lumen of the endoplasmic
reticulum (ER)5 (3–5). Synthesis of the dolichol-linked oligo-
saccharide (DLO) is a multistep process that initially generates
Man5GlcNAc2-PP-dolichol (M5-DLO) on the cytoplasmic side
of the ER (Fig. 1). M5-DLO is then flipped across the mem-
brane to the ER lumen where it is elaborated in a series of reac-
tions to mature DLO (mDLO). Metazoan mDLOs have a
Glc3Man9GlcNAc2 glycan, although mDLOs in other eu-
karyotes have smaller glycans. For example, mDLO in procyclic
forms of the parasitic protozoan Trypanosoma brucei has a
Man9GlcNAc2 glycan (6) that, after transfer to protein, is
trimmed by mannosidases to generate “processed” N-glycans
(Fig. 1).
The molecular machinery required for DLO assembly has
been largely identified, except for the lipid flippases responsible
for translocating M5-DLO and other dolichol-based lipids
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across the ERmembrane (Fig. 1) (3, 5, 7). This impasse appeared
to be broken when Ng et al. (8) and later Helenius et al. (9).
working with the yeast Saccharomyces cerevisiae, concluded
that the ER membrane protein Rft1 is required directly for
membrane translocation of M5-DLO. These investigators
showed that yeast cells in which Rft1 expressionwas reduced to
levels much lower than normal (though not nil) accumulate
M5-DLO and hypoglycosylate proteins as would be expected
for cells deficient in M5-DLO flippase activity. They also
showed that overexpression of Rft1 alleviated the poor growth
of alg11 cells that synthesize Man3GlcNAc2-PP-dolichol
(M3-DLO) rather thanM5-DLO on the cytoplasmic face of the
ER. Within the framework of their proposal that Rft1 is a DLO
flippase, they suggested that overexpression of Rft1 increased
the predicted low rate of M3-DLO flipping to a level that could
sustain the growth of alg11 cells.
The assignment of Rft1 as the M5-DLO flippase was chal-
lenged by biochemical studies. Sealed microsomes prepared
from Rft1-depleted and Rft1-replete yeast cells were indistin-
guishable in their ability to synthesize mDLO, indicating that
although Rft1 may have a critical role in mDLO biosynthesis in
vivo, it was dispensable in vitro (10). Further concerns with the
proposed role of Rft1 as theM5-DLO flippase were revealed by
biochemical reconstitution experiments.M5-DLO flippingwas
demonstrated in proteoliposomes reconstituted with rat liver
or yeast ERmembrane proteins (11–13). Flipping in this recon-
stituted system was highly specific (13); a nonbiological struc-
tural isomer of M5-DLO was not flipped, and M6-DLO and
larger DLO structures were flipped slowly, consistent with the
early work of Snider and Rogers (14). Importantly, proteolipo-
somes lacking Rft1 were identical in their activity to Rft1-con-
taining preparations, and biochemical fractionation of ER
membrane protein extracts prior to reconstitution revealed
that M5-DLO flippase activity could be resolved from Rft1 by a
variety of methods, including velocity sedimentation and ion
exchange chromatography (11, 12).
The cumulative data indicate that Rft1 is intimately involved
inmDLObiosynthesis; however, its specific role in the pathway
and its possible contribution toM5-DLO flipping remain enig-
matic. To address this issue, we sought to analyze mDLO bio-
synthesis in vivo in the complete absence of the protein. As this
could not be done in yeast where Rft1 is essential for viability
under standard growth conditions, we turned to T. brucei, an
early diverging eukaryotewith anN-glycosylation pathway sim-
ilar to that found in higher eukaryotes (15). T. brucei is a para-
sitic protozoan that causes sleeping sickness in humans and
nagana in animals throughout sub-Saharan Africa. Compared
with S. cerevisiae cells that grow rapidly and thus need N-gly-
cosylation for osmoprotective cell wall assembly, we reasoned
that the relatively slow-growing trypanosomesmight be able to
tolerate the absence of Rft1, especially if the protein provided an
accessory rather than a core function in DLO biosynthesis. We
identified the T. brucei Rft1 homologue and demonstrated that
it provides the essential function of Rft1 in yeast. We now
report that the procyclic form of T. brucei tolerates homozy-
gous null disruptions of the TbRft1 gene. Remarkably, the
TbRft1-null strains synthesize normal levels of mDLO and
transfer mDLO-derived glycans to protein but nevertheless
accumulate M5-DLO and underglycosylate proteins. Our
results show that M5-DLO flipping occurs in the complete
absence of Rft1 in vivo but that Rft1 nonetheless influences the
conversion of M5-DLO to M9-DLO.
EXPERIMENTAL PROCEDURES
Materials—Unless otherwise stated, all reagents were of ana-
lytical grade and purchased from Sigma or Merck. Restriction
enzymes were from Fermentas (St. Leon-Rot, Germany) and
antibiotics from Sigma, Invivogen (Nunningen, Switzerland),
or Invitrogen. EasyTag Expre35S35S protein labeling mix was
from PerkinElmer Life Sciences. BioMax MS and MXB films
were from GE Healthcare.
Trypanosome Cultures—T. brucei strain Lister 427 procyclic
forms were cultured at 27 °C in SDM-79 containing 5% heat-
inactivated fetal bovine serum. Rft1 knock-out clones were
grown under the same condition, in the presence of 15 g/ml
G418 for the single allele knock-out and an additional 10g/ml
blasticidin for the double allele knock-out clones.
Generation of TbRft1-null Cells—Constructs to replace the
endogenousTbRft1 genes were based on the pKO plasmid con-
taining resistance cassettes consisting of the following elements
(5 to 3): the EP1-EP2 procyclin intergenic region, a G418 or
blasticidin resistance gene, and the tubulin  intergenic
region (16). A 397-bp 5 and a 427-bp 3 recombination
sequence flanked the resistance cassettes. Recombination
sequences adjacent to the TbRft1 open reading frame were
obtained by PCR amplification using primers 5_forward
gcccaagcttacatgtcgctttaagttccgc and 5_reverse gcgaatcccacac-
FIGURE 1.DLO biosynthesis and protein N-glycosylation in T. brucei pro-
cyclic cells. Dolichyl phosphate (top left) is sequentially glycosylated by
UDP-GlcNAc- and GDP-Man-utilizing glycosyltransferases to generate
M5-DLO on the cytoplasmic side of the ER. M5-DLO is translocated across the
ER membrane by the M5-DLO flippase. In the ER lumen, it is extended to
mature M9-DLO by mannosyltransferases that use mannose phosphate
dolichol (MPD) as themannosyl donor. Mannose phosphate dolichol (bottom
left) is synthesized on the cytoplasmic face of the ER and flipped in by an
mannose phosphate dolichol flippase to participate in luminal mannosyl
transfer reactions. In procyclic form trypanosomes, oligosaccharyltransferase
(OST) transfers anM9 glycan frommDLO to Asn residues of Asn-Xaa-(Ser/Thr)
glycosylation sequons within ER-translocated proteins. The dolichyl diphos-
phate generated as a result is converted to dolichyl phosphate that then flips
back across the ER to reinitiate DLO biosynthesis. N-Glycans are trimmed by
luminalmannosidases to generate processed structures such as the example
on the right.
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caaaggtacagctgctgc for the 5-recombination sequence and
3_forward cgctctagagtggtgaaggcgctggttc and 3_reverse gcg-
gagctcagcttggagtccatgagtgg for the 3-recombination sequence
(HindIII, EcoRI, XbaI, and SacI restriction sites are underlined).
Prior to transfection into T. brucei 427 procyclic forms, plas-
mids were digested upstream and downstream of the recombi-
nation sequences using HindIII and SacI. Clones were obtained
by limiting dilution under antibiotic selection using 15 g/ml
G418 and/or 10 g/ml blasticidin. Clones were PCR-tested for
correct integration using primer 5 UTR_control ggaagcgcaat-
cattcagag, which binds 50 bp upstream of the 5 recombination
sequence, in combination with different reverse primers.
To introduce an ectopic copy of Rft1 into TbRft1-null cells,
TbRft1 was amplified with primers TbRft1_forward gcccaagct-
tatggacttcaaacgacagctg and TbRft1_reverse gccctcgagctactcgc-
cgcttctttttg and cloned into a pLEW100-based expression vec-
tor (17) (HindIII and XhoI restriction sites are underlined).
Clones were obtained by limiting dilution under antibiotic
selection using 2 g/ml puromycin.
Southern Blot Analysis—For Southern blot analysis, 1.2g of
AgeI or SacII/SmaI-digested genomicDNA fromwild-type and
mutant cells was separated on a 1% agarose gel and transferred
to Hybond-N nylon transfer membrane (GE Healthcare)
using 10 SSC buffer (150 mM Na3-citrate, pH 7.0, containing
1.5 M NaCl). The membrane was probed with a 427-bp 32P-
labeled PCR product of the TbRft1 3 recombination sequence
generated with the prime-a-gene labeling system (Promega,
Du¨bendorf, Switzerland). The hybridized probe was detected
by autoradiography using BioMax MS films in combination
with intensifying screens.
35S Labeling of Trypanosomes and Immunoprecipitation of
p67—Wild-type and TbRft1-null cells were labeled with
EasyTag Expre35S35S essentially as described before (18, 19).
Briefly, trypanosomes were washed twice in PBS and resus-
pended at 107/ml in pre-warmed (27 °C) Met/Cys-deficient
SDM-79 containing 5% dialyzed FBS for 10 min. Labeling was
initiated by the addition of [35S]Met/Cys to 100 Ci/ml. After
60 min of incubation, cells were washed with cold buffer and
resuspended in cold solubilization buffer (150mMNaCl, 50mM
Tris-HCl, pH 8.0, containing 1% Nonidet-40, 0.1% SDS, and
0.5% deoxycholate). After centrifugation for 5 min at 1500 g
in a microcentrifuge, mouse anti-p67 was added to the clear
supernatant and incubated under constant rotation for 60 min
at 4 °C. Antibody-bound p67 was precipitated using protein
A-agarose for 60min at 4 °C under rotation, washed, and resus-
pended in electrophoresis buffer.
Enzyme Treatments—Parasite lysates or immunoprecipi-
tated proteins were treated with N-glycosidase F (PNGase) or
endoglycosidase H (Endo H) according to the manufacturer’s
instructions.
SDS-PAGE, Autoradiography/Fluorography—Parasite lysates
or immunoprecipitated proteins were separated on 10% poly-
acrylamide gels under reducing conditions (20). 35S-Labeled
proteins were detected after fixation of the gel and exposure to
BioMax MS films at70 °C.
Fluorophore-assisted Carbohydrate Electrophoresis (FACE)
Analysis of Trypanosomal Glycoconjugates—Trypanosomes
were collected by centrifugation and washed twice with ice-
cold PBS.Methanol (room temperature) was added to the tube,
and the contents were disrupted by vigorously vortexing. The
suspensions were dried and processed for FACE analyses as
described (21, 22). In brief, after most lipids were removed by
extraction with chloroform/methanol (2:1, by volume) and
aqueous components removed by extraction with water, DLOs
were obtained by extraction with chloroform/methanol/water
(10:10:3, by volume). N-Linked glycoproteins remained in the
residual material. The glycan units of DLOs were released with
weak acid.N-Glycans were released with PNGase F and further
purified by ion exchange. All glycans were conjugated with 7-a-
mino-1,3-naphthalenedisulfonic acid (ANDS) and resolved on
an oligosaccharide profiling gel, with all loads normalized to
total protein in the chloroform/methanol/water (10:10:3) resi-
due. When necessary, the fluorescently conjugated glycans
were incubated in 50mM sodium citrate buffer, pH 5.5, for 18 h
at 37 °Cwith 100 units of EndoH (NewEnglandBiolabs) and/or
0.05 milliunits of -1,2-mannose-specific mannosidase (Asper-
gillus saitoi, Prozyme). Fluorescently labeled oligosaccharides
were detected with a Bio-Rad Fluor-S scanner and quantified
with Quantity-One software.
Flow Cytometry Analysis—Trypanosomes at mid-log phase
(107 parasites) were harvested by centrifugation at 1500 g for
10 min at 4 °C and resuspended in 200 l of cold SDM-79.
Concanavalin A-FITC conjugate was added to a final concen-
tration of 3 g/ml. After 1 h of incubation in the dark on ice, 1
ml of cold SDM-79 was added, and parasites were centrifuged
as above. After washing once in cold SDM-79, trypanosomes
were resuspended in 2ml of cold SDM-79 and analyzed by flow
cytometry (BDFACSCalibur or FACScan) at a concentration of
5 105 cells/ml. Datawere analyzed using flow cytometry anal-
ysis software FlowJo.
Immunofluorescence Microscopy—Parasites were processed
for immunofluorescence microscopy exactly as described
before (23), using antibodies against p67 (19) and TbCatL (24)
at dilutions of 1:1000 and 1:500, respectively. Secondary anti-
bodies Alexa Fluor 594 goat -mouse IgG (Invitrogen) and
Alexa Fluor 488 goat -rabbit IgG (Invitrogen) were used at
dilutions of 1:1000.
RESULTS
T. brucei Rft1 Is Functionally Equivalent to S. cerevisiae Rft1—
We identified an Rft1 orthologue inT. brucei by BLAST search-
ing the predicted proteome of T. brucei strain TREU 927 using
human and S. cerevisiaeRft1 sequences as queries.We retrieved
a single orthologous sequence, Tb11.01.3540, that was anno-
tated as a 598-amino acid hypothetical protein. Topology pre-
diction programs indicated that Tb11.01.3540 is a membrane
protein with multiple transmembrane spans. To determine
whether Tb11.01.3540 could functionally substitute for yeast
Rft1 (ScRft1), we used a haploid yeast strain (YG1137) (9) in
which ScRft1 is expressed under the control of the glucose-
repressibleGAL1–10 promoter. On shifting YG1137 cells from
galactose- to glucose-containing medium, ScRft1 expression is
repressed and the cells fail to grow (Fig. 2A). At the same time,
carboxypeptidase Y (CPY), a vacuolar protease with fourN-gly-
cans, becomes hypoglycosylated, with ever fewer glycosylation
sites on the protein being occupied as the incubation time in
Protein N-Glycosylation in an Rft1-null Eukaryote
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glucose-containing media is increased and ScRft1 levels
decrease (Fig. 2B, lanes indicated TbRft1) (9–11). Heterolo-
gous expression of Tb11.01.3540 enabled YG1137 cells to grow
on glucose-containing media (Fig. 2A) and prevented CPY
hypoglycosylation (Fig. 2B, lanes indicatedTbRft1) indicating
that the trypanosome protein, henceforth TbRft1, is function-
ally equivalent to ScRft1.
TbRft1 Is Nonessential in Procyclic FormTrypanosomes—We
used homologous recombination to replace the TbRft1 alleles
in diploid procyclic cells with G418 and blasticidin resistance
genes, eliminating the ability to express any form of TbRft1
protein. We recovered viable clones of TbRft1-null trypano-
somes that grew nearly normally (Fig. 3A). The generation time
of two independent TbRft1-null clones was 15.3  0.9 and
14.4  0.2 h, compared with 11  0.2 and 13.1  0.5 h for
wild-type cells and single knock-out cells, respectively. These
data suggest that growth rate is sensitive to TbRft1 gene dosage
(in contrast to effects on glycosylation, see below). Southern
blot analyses (Fig. 3B) confirmed that we had indeed disrupted
both alleles of TbRft1 and that the growth of the cells was not
due to inappropriate integration of the drug resistance genes
elsewhere in the genome rather than at the TbRft1 locus. We
conclude that TbRft1 is a nonessential protein in T. brucei pro-
cyclic forms in culture.
To determine whether the TbRft1-null trypanosomes had a
glycosylation defect, we incubated the cells with FITC-ConA, a
fluorescent conjugate of the mannose-binding lectin conca-
navalin A, and quantified cell surface fluorescence by flow
cytometry. TbRft1-null trypanosomes bound 75% less
FITC-ConA than wild-type cells (Fig. 3C). This was specifi-
cally due to the lack of Rft1, as FITC-ConA binding could be
restored by ectopic expression of TbRft1 (Fig. 3D, histogram
labeled rescue). Thus, despite their robust growth characteris-
tics, the Rft1-null cells show decreased levels of cell surface
glycosylation.
Dolichol-linked Oligosaccharide Synthesis and Protein
N-Glycosylation in TbRft1-null Cells—To examine the glyco-
sylation phenotype of the Rft1-null trypanosomes in more
detail, we used FACE (21), a sensitive method to quantify
steady-state levels of oligosaccharides. The cells were treated
with organic solvent to extract DLOs and precipitate proteins.
Oligosaccharides were released from DLOs and N-glycopro-
teins with mild acid and peptide:N-glycosidase F (PNGase F)
treatment, respectively.N-Glycans were further purified by ion
exchange chromatography to enrich neutral glycans, including
high mannose structures. All glycans were conjugated with
ANDS fluorophore and analyzed on an oligosaccharide profil-
ing gel.
The profile of DLOs (Fig. 4A) in TbRft1-null trypanosomes
was striking. The steady-state level of M9-DLO in the TbRft1-
null cells (24.2 2.2 pmol/mg) was similar to that in wild-type
cells (22.8 0.2 pmol/mg) indicating that the null cells have an
intact DLO assembly pathway. However, the steady-state level
of M5-DLO in the TbRft1-null trypanosomes was 40-fold
higher than that in wild-type cells (382.7 34 versus 8.7 0.9
pmol/mg). Also apparent was the accumulation of M6-DLO,
M7-DLO, and M8-DLO (Fig. 4A), whose consumption has no
obvious requirement for the M5-DLO flippase. Cumulative
results obtained from independent experiments and individual
TbRft1-null clones (Table 1) indicate that this pattern is highly
reproducible; TbRft1-null cells have a 30–100-fold higher
steady-state level of M5-DLO compared with wild-type cells
but an essentially normal level of M9-DLO (Table 1). Although
a reduction in TbRft1 gene dosage had a mild effect on the rate
of growth (Fig. 3A), steady-state levels of the various glycocon-
jugates were similar in wild-type and heterozygous trypano-
somes (Table 1).
FIGURE 2.TbRft1 is functionally equivalent to S. cerevisiaeRft1.A,YG1137
yeast cells (in which Rft1 expression is controlled by the glucose-repressible
GAL1–10 promoter) were transfected with an episomal URA3 plasmid encod-
ing TbRft1 () or an empty vector (). Serial dilutions were spotted on mini-
mal uracil-free solid media containing either 2% glucose (Glc) or galactose
(Gal), and incubated for 2 days at 30 °C. B, YG1137 cells were transfected as in
A and grown on Glc- or Gal-containingminimal media at 30 °C. Extracts were
prepared at the indicated times and analyzedby SDS-PAGE and immunoblot-
ting with anti-carboxypeptidase Y (CPY) antibodies. Mature and hypoglyco-
sylated forms of CPY, particularly evident in the 20 h sample from Glc-grown
cells transfected with the empty vector, are indicated by dots.
FIGURE 3. Characterization of TbRft1-null trypanosomes. A, cumulative
growth of wild-type and mutant T. brucei procyclic forms. B, Southern blot
analysis. AgeI or SacII/SmaI-digested genomic DNA from wild type and
mutant trypanosomes was separated on an agarose gel, transferred to
hybond-Nnylon transfermembrane, andprobedwith a 427-bp 32P-labeled
PCR product of the TbRft1 3 recombination sequence. The hybridized probe
was detected by autoradiography. C, ConA reactivity. Wild-type (wt) and
TbRft1-null (/) trypanosomes were fixed and incubated with or without
FITC-ConA. The extent of labeling was determined by flow cytometry. The
corresponding profiles of unlabeled cells are shown as line traces, without
fill. D, flow cytometry analysis of TbRft1-null cells expressing TbRft1 (res-
cue) compared with TbRft1-null and wild-type trypanosomes. Analysis
was done as in C.
Protein N-Glycosylation in an Rft1-null Eukaryote
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Weconsideredwhether the accumulatedM5-DLO is a direct
product of the DLO biosynthetic pathway (“biosynthetic M5”
(Fig. 4E)) or whether it is derived from mature M9-DLO as a
result of the action of cellular mannosidases (“processed M5”
(Fig. 4E)). To distinguish these possibilities, we determined the
susceptibility of the accumulated M5-DLO to Endo H and
1,2-mannosidase (1,2m). As outlined schematically in Fig.
4E, biosynthetic M5 is susceptible to 1,2m yielding
Man3GlcNAc2-ANDS but resistant to EndoH; in contrast, pro-
cessed M5 is susceptible to Endo H (the GlcNAc-ANDS prod-
uct is not retained within the resolving gel) but resistant to
1,2m. The glycosidase digests shown in Fig. 4B indicate clearly
that the accumulated M5-DLO is “biosynthetic,” i.e. it corre-
sponds to a DLO biosynthesis intermediate.
Wenext analyzed neutralN-glycans released by PNGase F.T.
brucei procyclic forms almost exclusively make high mannose
type N-glycans (25). The profile of N-glycans seen in TbRft1-
null trypanosomeswas identical to that inwild-type cells except
that the total level of N-glycans was, on average, 67% lower
(Fig. 4C and Table 1), consistent with the 75% lower surface
reactivity of TbRft1-null cells toward ConA (Fig. 3C). The full
range of N-glycans was observed in TbRft1-null cells, from
Man5GlcNAc2 to Man9GlcNAc2. Glycosidase digests (Fig. 4D,
illustrated schematically in Fig. 4E) indicated that the
Man5GlcNAc2 species recovered in the N-glycan fraction cor-
responds to processedM5 (Fig. 4E). This result indicates that in
Rft1-null cells a higher order oligosaccharide such as M9 is
transferred to proteins and subsequently trimmed by cellular
mannosidases to processed M5. The cumulative data reveal
that TbRft1-null trypanosomes have a complete N-glycosyla-
tion pathway but nevertheless accumulate large amounts of the
M5-DLO biosynthetic intermediate that is not directly trans-
ferable to protein.
N-Glycosylation of p67 in TbRft1-null Cells—To refine our
analyses of N-glycosylation in the TbRft1-null trypanosomes,
we focused on a specific protein and chose p67, a well charac-
terized lysosomal N-glycoprotein with 14 N-glycosylation sites
(19).We immunoprecipitated p67 from trypanosomes that had
been metabolically labeled with [35S]methionine/cysteine and
analyzed the protein by SDS-PAGE and fluorography. Fig. 5A
shows the expected 100-kDa band for fully glycosylated p67
in wild-type cells and a lower molecular weight (72 kDa) dif-
fuse band in TbRft1-null cells (Fig. 5A, compare lane 2 with
lane 1). Treatment with either Endo H or PNGase F converted
the diffuse band to an67-kDa product (Fig. 5A). Thus, p67 in
FIGURE 4.M9-DLO is synthesized and used forN-glycosylation in TbRft1-
null cells while biosyntheticM5-DLO accumulates.DLOs and total neutral
N-glycans from wild-type (wt), TbRft1-heterozygous (/), and TbRft1-null
(/) trypanosomes were analyzed by FACE. The positions of glucose oligo-
mers (G4 to G7) and dolichol-linked glycan standards (M3-G3M9) are shown.
A,DLOs fromduplicate samples ofwild-type (lanes 2 and 3), TbRft1-null (lanes
4 and 5), and TbRft1-heterozygous (lanes 6 and 7) cells. Glycanswere released
from the DLO fraction and labeled with ANDS prior to analysis. B, DLOs from
rodent liver (control), or wild type (wt), or TbRft1-null trypanosomes. ANDS-
labeled glycans were incubated in the absence or presence of Endo H or
1,2m as indicated. Cleavage by Endo H releases GlcNAc-ANDS, with loss of
fluorescent label from theparent glycan.C, total neutralN-glycans, as forA.D,
analysis of total neutral N-glycans by glycosidase digestion, as for B, except
that the control usedwas a DLO preparation from rodent kidney, which has a
relatively high proportion of nonglucosylated DLOs. E, schematic showing
the glycosidase digestion pattern obtained for various glycans. bM5, biosyn-
thetic biantennary Man5GlcNAc2; pM5, processed triantennary Man5GlcNAc2
(see also Fig. 1).
TABLE 1
Steady-state levels of M9-DLO, M5-DLO, total DLOs and total neutral N-glycans in wild-type, TbRft1-null, and single knock-out
trypanosomes
Mean range of duplicatemeasurements is quoted as picomoles of glycoconjugate permg of protein; NDmeans not determined. Two different TbRft1-null clones (A3 and
B1(2)) were analyzed, alongside single knock-out (3F) and wild-type (427) cells. Raw data for experiment 1 are depicted in Fig. 3, A and C.
Experiment Glycoconjugate 427 (/) A3 (/) B1(2) (/) 3F (/)
1 M9-DLO 22.8 0.2 24.2 2.2 ND 24.2 1.6
M5-DLO 8.7 0.9 382.7 34 ND 12.3 0.5
	 DLO 32.2 1.4 423.7 36 ND 40.4 2.2
	 N-glycans 687 16 294 36 ND 727 2
2 M9-DLO 17.4 0.6 6.4 0.8 14.2 1.8 25.2 0.4
M5-DLO 8.4 0.4 248.2 2.2 840.8 0.4 28.6 3.2
	 DLO 25.8 1 254.6 3 855 2.2 54 2.8
	 N-glycans 857 100 323 27 454 16 907 82
Protein N-Glycosylation in an Rft1-null Eukaryote
20620 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 288•NUMBER 28•JULY 12, 2013
 at U
niversitaetsspital-Bibliothek U
SB on M
arch 13, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
TbRft1-null cells is N-glycosylated, and the glycans are fully
Endo H-sensitive indicating that they have the expected oligo-
mannose structure.
We observed that Endo H-treated p67 from TbRft1-null
trypanosomes migrates slightly faster than the corresponding
sample from wild-type cells (Fig. 5A, compare lane 4 with lane
3). This is likely because fewer N-glycosylation sites are occu-
pied in p67 from TbRft1-null cells, and therefore, there are
fewer GlcNAc residues left on the protein after Endo H cleav-
age. Differences in migration are also observed in PNGase
F-treated p67 samples (Fig. 5A, compare lane 6 with lane 5). In
this case, lower site occupancy would result in fewer Asn resi-
dues being converted into negatively chargedAsp residues after
PNGase F digestion of p67 from TbRft1-null trypanosomes,
making this protein migrate slightly faster than its counterpart
from wild-type cells. We conclude that fewer N-glycosylation
sites are occupied in p67 fromTbRft1-null cells compared with
wild-type cells, thus explaining its faster and more diffuse
migration on SDS-PAGE. Based on gel mobility, we estimate
that p67 in the TbRft1-null trypanosomes has 2–4 N-glycans.
Despite being underglycosylated, p67 is correctly localized
to the lysosome in TbRft1-null cells. Immunofluorescence
microscopy (Fig. 5B) revealed a single organelle in the region
between the nucleus and the posterior flagellar pocket that was
stained with anti-p67 antibodies as well as with antibodies
against TbCatL, a trypanosomal cathepsin L orthologue (24).
DISCUSSION
Wegenerated anRft1-null cell,making it possible for the first
time to characterize quantitatively the consequences of com-
plete Rft1 absence by measuring the steady-state levels of key
DLO intermediates and N-glycoproteins. In contrast, previous
analyses of Rft1 function in vivowere done on cells in which the
protein was acutely depleted but not eliminated (9). Our results
clearly show that TbRft1-null procyclic trypanosomes can exe-
cute the entire ER N-glycosylation pathway, i.e. synthesis of
M9-DLO, transfer of Man9GlcNAc2 to proteins, and trimming
ofN-glycans. However,measurements of the steady-state levels
of DLO intermediates by FACE show that although M9-DLO
levels are unaffected, the mutant cells accumulate large
amounts of the M5-DLO biosynthetic intermediate. Accumu-
lation of the downstream intermediates M6-DLO, M7-DLO,
and M8-DLO was also detected. These data indicate that
TbRft1 impacts the multistep conversion of M5-DLO to
M9-DLO.
Our results are inherently inconsistent with the assignment
of Rft1 (8, 9) as theM5-DLO flippase. Another protein, yet to be
identified, very likely plays this role because spontaneous flip-
flop ofM5-DLO (26) is too slow to supply theDLObiosynthetic
pathway in TbRft1-null trypanosomes; the t1⁄2 forM5-DLO flip-
ping in synthetic bilayers is predicted to be100 h, i.e.much
slower than that for common phospholipids (27). It is formally
possible that M5-DLO flipping in the mutant cells is the result
of a nonspecific process, involving membrane factors that do
not normally serve this function. However, given our earlier
demonstration of a chromatographically discrete protein frac-
tion with structure-specific M5-DLO flipping activity in vitro
(11–13), there is little justification for invoking such a model.
For insights into the observed steady-state levels ofM5-DLO
and M9-DLO in wild-type and TbRft1-null cells, we modeled
theDLOpathway as a sequential, irreversible series of reactions
in which a source (S) is converted to M5-DLO, then to
M9-DLO, and finally to product(s) (P). This simplification is
possible because in steady state, a series of reactions can be
replaced by a single reaction without invoking a rate-limiting
step. Thus, in Reaction 1,
S O¡
k1
M5  DLO O¡
k2
M9 DLO O¡
k3
P
REACTION 1
where the rate constant k1 describes the set of reactions leading
to the production of M5-DLO, the rate constant k2 character-
izes the multistep conversion of M5-DLO toM9-DLO, and the
rate constant k3 indicates the conversion of M9-DLO to prod-
ucts. The steady-state levels of M5-DLO and M9-DLO are
shown in Equation 1,
M5  DLOss 
k1/k2S
M9 DLOss 
k2/k3M5 DLOss 
k1/k3S (Eq. 1)
Thus, the simplest explanation for the100-fold higher level of
M5-DLOss in TbRft1-null cells is that k2 is100-fold lower in
these cells compared with wild-type cells. This change does not
affect M9-DLOss, which does not depend on k2.
How does TbRft1 affect k2, i.e. conversion of M5-DLO to
M9-DLO? The processes encapsulated in k2 are minimally the
M5-DLO flipping event and the four luminalmannosyl transfer
reactions. As the cumulative biochemical data reported earlier
FIGURE 5. Analysis of p67. A, analysis of p67 from wild-type and TbRft1-null
cells. Trypanosomesweremetabolically labeledwith 35S-labeled amino acids
and lysed, and p67 was immunoprecipitated and analyzed by SDS-PAGE and
fluorography, either directly or after Endo H or PNGase F treatment. B, fluo-
rescencemicrographs obtained usingDAPI, as well as antibodies against p67
and TbCatL. DAPI staining reveals kinetoplast and nuclear DNA.DIC, differen-
tial interference contrast.
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(10–12) and the in vivo results presented here demonstrate that
M5-DLO flipping does not require Rft1, and the luminal man-
nosyltransferases are known (Alg3, Alg9, and Alg12, with Alg9
carrying out two of the four mannosylations (7)), we conclude
that Rft1 carries out its role separately from the coremachinery
required for conversion of M5-DLO to M9-DLO. We suggest
that Rft1 plays an accessory albeit important role in M9-DLO
biosynthesis. For example, it may control k2 by functioning as a
DLO chaperone to supply M5-DLO to the flippase or manno-
syltransferases or to increase the chemical activity of M5-DLO
by preventing its possible aggregation. Similar considerations
apply toM6-,M7-, andM8-DLOas these lipids also accumulate
in the TbRft1-null cells. Alternatively, it could stabilize a com-
plex of the luminal mannosyltransferases, thus enabling sub-
strate channeling. Complex formation involving components
of the DLO biosynthetic machinery has been previously
reported (28, 29). In this context, it is interesting to note that
disease-causing mutations in human Rft1 are located in hydro-
philic loop regions of the protein that are predicted to be in the
ER lumen (30); these functionally important loops could con-
ceivably be involved inRft1’s proposed role as luminalM5-DLO
chaperone or its proposed role as a partner of luminal manno-
syltransferases. As discussed previously (11, 12), Rft1’s function
may resemble that of Lec35/MPDU1, ametazoanprotein that is
involved in luminal mannosyl transfer reactions in vivo (31).
Lec35/MPDU1was originally thought to be an excellent candi-
date for the mannose-phosphate dolichol flippase (Fig. 1), but
the current consensus is that it acts as a dolichyl-lipid chaper-
one (31, 32).
Why isN-glycosylation reduced even thoughM9-DLOss lev-
els are normal in TbRft1-null cells? Steady-statemeasurements
do not give information about flux. Thus, although M9-DLOss
levels are normal, the rates ofM9-DLOsynthesis and consump-
tion may be coordinately reduced by factors (yet to be deter-
mined) secondary to the absence of TbRft1.M9-DLO is subject
to at least two known fates (collectively described by the rate
constant k3 in Reaction 1), consumption by oligosaccharyl-
transferase for protein N-glycosylation and turnover, possibly
by regulated cleavage of its pyrophosphate linkage (22). The
balance between the two fates can be altered without affecting
k3 or M9-DLOss. Thus, with less M9-DLO being consumed for
N-glycosylation, greater turnover could be accommodated in
the TbRft1-null strain. However, it is unlikely that mannose
6-phosphate-dependent hydrolysis of DLOs described by Gao
et al. (22, 33) could contribute to DLO turnover because
M9-DLO appears not to be a substrate for this process. Alter-
natively,M9-DLO levels could be limiting in bothwild-type and
TbRft1-null trypanosomes. In this event, the reduced rate of
production of M9-DLO in the TbRft1-null cells could account
for the observation of fewer glycans per protein.
Where does M5-DLO accumulate in TbRft1-null cells?
Wild-type procyclic trypanosomes normally transferM9 oligo-
saccharides to proteins and process these to triantennary M5
structures (Fig. 1). When biosynthetic M5-DLO is the only
donor available to oligosaccharyltransferase in procyclic forms
of T. brucei, proteins are underglycosylated and N-glycans are
aberrantly processed to biantennary complex structures (34).
The M5-DLO that accumulates in TbRft1-null cells could
potentially compete with mature M9-DLO in the oligosaccha-
ryltransferase reaction, resulting in biantennary complex
N-glycans that would be resistant to Endo H digestion. This is
not the case; analysis of total N-glycans (Fig. 4D), as well as
N-glycans on p67 (Fig. 5A), indicates structures that are com-
pletely susceptible to Endo H. The M5 structures that we
detected in N-glycans were also Endo H-sensitive; they were
derived by normal processing of mature M9 N-glycans and did
not originate by direct transfer of biosynthetic M5. Thus,
M5-DLO does not compete with M9-DLO and therefore must
not have access to the site of oligosaccharyl transfer.
Either of two contrasting models could account for the seg-
regation of accumulatedM5-DLO from the site of oligosaccha-
ryl transfer in the ER: model 1, M5-DLO accumulates on the
cytoplasmic side of the ER, andmodel 2,M5-DLO accumulates
on the luminal side of the ER, perhaps in an aggregated form
with low chemical activity or in a region of the ER that is later-
ally segregated from the oligosaccharyltransferase. Examples of
lateral segregation of reactions within a single pathway in the
ER have been previously noted (35, 36). Themodels have impli-
cations for possible functions of Rft1. In model 1, Rft1 would
function as an accessory protein to supply M5-DLO to the flip-
pase on the cytoplasmic side of the ER, and in model 2, Rft1’s
function would be on the luminal side of the ER, possibly to
prevent M5-DLO aggregation and increase its chemical activ-
ity, or chaperone M5-DLO between ER domains.
The two models predict different transbilayer orientations
for M5-DLO; in model 1, M5-DLO would be mainly oriented
toward the cytoplasm, and in model 2, M5-DLO would be able
to flip bidirectionally between leaflets. Current biochemical
approaches, e.g. capturing M5-DLO on the cytoplasmic side of
intact ER preparations with a lectin (11, 14), would not be able
to distinguish between these models as M5-DLO would be
quantitatively captured in both cases. Indeed, unless it is known
that the transbilayer distribution of M5-DLO is stable during
the analysis, it would be difficult tomake any conclusions about
its orientation. Development of suitable techniques to distin-
guish between these models remains an objective for future
work.
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